Global DNA Vaccine Market Outlook 2025
Several DNA vaccines are currently in clinical trials which are expected to get approval soon. The industry has garnered interest of investors with funds pouring in from industry over and above development funding provided by government. Rise in R&D activities in the industry is anticipated to propel growth of the market.
The report “Global DNA Vaccine Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global DNA vaccine market overall as well as across various geographies. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global DNA vaccine market. The report has been segmented as following:-
Geographical Coverage
The report “Global DNA Vaccine Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global DNA vaccine market overall as well as across various geographies. Regional analysis is done across major markets in North America, Europe and Asia Pacific.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities in global DNA vaccine market. The report has been segmented as following:-
Geographical Coverage
- North America
- Europe
- Asia Pacific
- Novartis International AG
- Merck & Co. Inc.
- GlaxoSmithKline plc
- Sanofi Pasteur SA
- Pfizer Inc.
- Astellas Pharma
- Dendreon Corporation
1. EXECUTIVE SUMMARY
2. RESEARCH METHODOLOGY
3. DNA VACCINES
3.1 Vaccines
3.2 Overview
3.2.1 History of DNA Vaccine
3.2.2 Components of Plasmid DNA Vaccine
3.3 DNA Vaccine Mechanism
3.4 DNA Vaccine Delivery Methods
4. MARKET ANALYSIS
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by End-User
4.2.2 Market Share by Clinical Trials
4.2.3 Market Share by Region
5. REGIONAL ANALYSIS
5.1 North America
5.1.1 Market Sizing (Actual & Forecasted)
5.2 Europe
5.2.1 Market Sizing (Actual & Forecasted)
5.3 Asia Pacific
5.3.1 Market Sizing (Actual & Forecasted)
6. MARKET DYNAMICS
6.1 Industry Trends & Developments
6.1.1 DNA Vaccine Clinical Pipeline
6.1.2 Mergers & Acquisitions
6.1.3 Investments in the Industry
6.2 Growth Drivers
6.2.1 Higher Incidences of Infectious Diseases
6.2.2 Increasing Adoption in Animal Healthcare
6.2.3 Growing Demand for Novel Vaccines
6.2.4 Advantages over Conventional Vaccines
6.3 Challenges
6.3.1 Ambiguous Regulatory System
6.3.2 Less Market Penetration
6.3.3 Incompatibility with Other Vaccines
7. COMPETITIVE LANDSCAPE
8. COMPANY PROFILES
8.1 Novartis International AG
8.2 Merck & Co., Inc.
8.3 GlaxoSmithKline plc.
8.4 Sanofi Pasteur SA
8.5 Pfizer Inc.
2. RESEARCH METHODOLOGY
3. DNA VACCINES
3.1 Vaccines
3.2 Overview
3.2.1 History of DNA Vaccine
3.2.2 Components of Plasmid DNA Vaccine
3.3 DNA Vaccine Mechanism
3.4 DNA Vaccine Delivery Methods
4. MARKET ANALYSIS
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by End-User
4.2.2 Market Share by Clinical Trials
4.2.3 Market Share by Region
5. REGIONAL ANALYSIS
5.1 North America
5.1.1 Market Sizing (Actual & Forecasted)
5.2 Europe
5.2.1 Market Sizing (Actual & Forecasted)
5.3 Asia Pacific
5.3.1 Market Sizing (Actual & Forecasted)
6. MARKET DYNAMICS
6.1 Industry Trends & Developments
6.1.1 DNA Vaccine Clinical Pipeline
6.1.2 Mergers & Acquisitions
6.1.3 Investments in the Industry
6.2 Growth Drivers
6.2.1 Higher Incidences of Infectious Diseases
6.2.2 Increasing Adoption in Animal Healthcare
6.2.3 Growing Demand for Novel Vaccines
6.2.4 Advantages over Conventional Vaccines
6.3 Challenges
6.3.1 Ambiguous Regulatory System
6.3.2 Less Market Penetration
6.3.3 Incompatibility with Other Vaccines
7. COMPETITIVE LANDSCAPE
8. COMPANY PROFILES
8.1 Novartis International AG
8.2 Merck & Co., Inc.
8.3 GlaxoSmithKline plc.
8.4 Sanofi Pasteur SA
8.5 Pfizer Inc.
